Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 27;14:199–209. doi: 10.1016/j.isci.2019.03.022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Validation of Extracellular Vesicle Isolation Procedure

(A) Upper panel: A representative immunoblotting is shown for CD63 and CD81 across 10 iodixanol density gradient fractions. The two rightmost lanes represent the input material before iodixanol separation and a total cell lysate (TCL) of the EV donor cells. Lower panel: a lighter exposure of the two rightmost lanes shown in the upper panel, also representing the input material (“Input” in upper panel or EVs in lower panel) and TCL of donor cells.

(B) Upper panel: Immunoblotting is shown for TSG101 and CD9 across 10 density gradient fractions. The two rightmost lanes represent the input material before iodixanol separation and a total cell lysate (TCL) of the donor cells. Lower panel: a lighter exposure of the two rightmost lanes shown in the upper panel, also representing the input material (noted as “Input” in upper panel and “EVs” in the lower panel) and TCL of EV donor cells. Results from (A) were obtained under non-reducing conditions, and results from (B) were obtained under reducing conditions.

(C) Immunoblotting is shown for calnexin across 10 density gradient fractions. The rightmost lane represents the TCL from PC3 cells. Results were obtained under non-reducing conditions.